scholarly journals KNOWLEDGE AND CARE PATHWAY EVOLUTION FOR PATIENTS WITH METASTATIC BREAST CANCER BETWEEN 2015 AND 2021: RESULTS’ COMPARISON OF THE RÉALITÉS 1 AND 2 FRENCH SURVEYS

The Breast ◽  
2021 ◽  
Vol 59 ◽  
pp. S45-S46
Author(s):  
Lefeuvre Claudia ◽  
Frenel Jean-Sebastien ◽  
Moley-Massol Isabelle ◽  
Guéroult-Accolas Laure ◽  
Debiais Dominique ◽  
...  
2020 ◽  
Author(s):  
Antoine Garnier-Crussard ◽  
Marine Haution ◽  
Mathilde Gueret-Du-Manoir ◽  
Quitterie Reynaud ◽  
Nathalie Freymond ◽  
...  

Abstract Background: Novel coronavirus (COVID-19) pandemic cause by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) threatens the world for few months. Few cases of prolonged positivity of viral tests and clinical recurrence of COVID-19 have been described. We report the case of a 78-year-old woman with metastatic breast cancer who developed possible COVID-19 recurrence in a post-acute and rehabilitation unit. Case presentation: A 78-year-old woman with metastatic breast cancer and hypertension developed COVID-19. After symptom improvement and RT-PCR negativation, she regained symptom (fever, fall) and lymphopenia on Day 26 and we note a turned positive RT-PCR even though she was tested positive for antibody against SARS-CoV-2. After the diagnosis of possible COVID-19 recurrence, she was transferred back to an acute “COVID-19” unit and she then quickly clinically recovered. Conclusions: This clinical case allows us to discuss the risk of recurrence and possible specific causes in older patients. Moreover, prolonged symptoms and lymphopenia could be associated to worse outcomes in older patients. Finally, at a collective level, even if traces of virus detected by RT-PCR were not necessarily correlated with the contagiousness, the importance of possible COVID-19 recurrence in the care pathway for older adults must be taken into account, since they are often surrounded by frail older people.


Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2308
Author(s):  
Marloes E. Clarijs ◽  
Jacob Thurell ◽  
Friedrich Kühn ◽  
Carin A. Uyl-de Groot ◽  
Elham Hedayati ◽  
...  

Metastatic breast cancer (MBC) patients are almost always treated to minimize the symptom burden, and to prolong life without a curative intent. Although the prognosis of MBC patients has improved in recent years, the median survival after diagnosis is still only 3 years. Therefore, the health-related quality of life (HRQoL) should play a leading role in making treatment decisions. Heterogeneity in questionnaires used to evaluate the HRQoL in MBC patients complicates the interpretability and comparability of patient-reported outcomes (PROs) globally. In this review, we aimed to provide an overview of PRO instruments used in real-world MBC patients and to discuss important issues in measuring HRQoL. Routinely collecting symptom information using PROs could enhance treatment evaluation and shared decision-making. Standardizing these measures might help to improve the implementation of PROs, and facilitates collecting and sharing data to establish valid comparisons in research. This is a prerequisite to learn about how they could impact the clinical care pathway. In addition, the prognostic value of intensified PRO collection throughout therapy on survival and disease progression is promising. Future perspectives in the field of PROs and MBC are described.


Sign in / Sign up

Export Citation Format

Share Document